Recent MIST News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 02:00:21 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/01/2024 09:52:12 PM
- Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants • GlobeNewswire Inc. • 02/28/2024 09:37:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:06:50 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/15/2024 01:56:08 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 12:10:54 PM
- Milestone Pharmaceuticals Shares Sink 24% After Receiving Rejection from FDA • Dow Jones News • 12/26/2023 01:54:00 PM
- Milestone Pharmaceuticals' Etripamil Nasal Spray Application Gets FDA's Refusal to File Letter • Dow Jones News • 12/26/2023 12:57:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 12:15:30 PM
- Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference • PR Newswire (Canada) • 11/21/2023 12:00:00 PM
- Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference • PR Newswire (US) • 11/21/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 12:05:49 PM
- Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates • PR Newswire (US) • 11/13/2023 11:57:00 AM
- Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates • PR Newswire (Canada) • 11/13/2023 11:57:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 11:37:33 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 11:09:40 AM
- Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023 • PR Newswire (Canada) • 11/11/2023 03:00:00 PM
- Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023 • PR Newswire (US) • 11/11/2023 03:00:00 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/09/2023 09:43:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 02:07:04 PM
- Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR • PR Newswire (US) • 11/07/2023 12:00:00 PM
- Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR • PR Newswire (Canada) • 11/07/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2023 08:05:28 PM
- Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil • PR Newswire (Canada) • 10/24/2023 11:00:00 AM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM